Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Pfizer Inc. (PFE) - free report >>
Moderna, Inc. (MRNA) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer Inc. (PFE) - free report >>
Moderna, Inc. (MRNA) - free report >>
Image: Bigstock
Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus
Stocks of makers of COVID vaccines, Moderna (MRNA - Free Report) , Pfizer (PFE - Free Report) , Novavax (NVAX - Free Report) and BioNTech (BNTX - Free Report) rose on Friday on reports of a new bat coronavirus being discovered in China.
What is the New Coronavirus?
Some scientists at Wuhan Institute of Virology, China said they had discovered a new coronavirus called HKU5-Cov-2 in bats that has the potential to be transferred to humans. Per reports, the virus belongs to the same family of coronaviruses as SARS-CoV-2, the virus that caused the deadly COVD-19 pandemic.
The virus has shown the potential to enter human cells by binding to a protein called ACE2 that is found in humans and other mammals.
The HKU5-Cov-2 also shares similarities with the viruses that cause Middle East Respiratory Syndrome or MERS causing similar symptoms like fever, cough, fatigue, sneezing and breathlessness. However, the HKU5-Cov-2 virus has not been found in humans yet.
What’s Behind the Rise of MRNA, PFE & NVAX Stocks?
Pfizer and partner BioNTech and Moderna gave the world the first mRNA-based vaccines to combat COVID-19 in the second half of 2021. However, with the end of the pandemic, sales of their COVID vaccines have waned due to lack of demand. The companies have, time and again, updated their COVID vaccines, but this has not helped sales improve much. Novavax’s protein-based vaccine was launched much later in August 2022.
On Friday, while Moderna rose 5.3%, Pfizer was up 1.5%. Novavax rose 0.9% and BioNTech rose 1.8%. The stocks rose in anticipation that the new virus in China could trigger another pandemic in the future, which, in turn, can result in demand for new vaccines to combat the virus, either through new formulations or updates to existing vaccines.
However, though the virus has shown the potential to infect humans, the risk of HKU5-Cov-2 causing a pandemic like COVID-19 is low as the HKU5-CoV-2 virus has significantly lower efficiency in binding to human ACE2 compared to SARS-CoV-2. This means that the chances of widespread human transmission are low.
Zacks Rank of MRNA, PFE, NVAX and BNTX
MRNA, NVAX and PFE have a Zacks Rank #3 (Hold) each, while BioNTech has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.